Four AI Drug Discovery Stocks On Sale – 50% Off

Using artificial intelligence (AI) to optimize the drug discovery process is an AI healthcare thesis that’s probably one of the more appealing and least mature when it comes to how machine learning will change industries. While themes like robotic process automation (RPA) and AI chips are reaching maturity and reaping rewards, we’ve yet to see some real breakthroughs come out of using machine learning to develop new drugs.

In September of last year, we published a piece Comparing Four AI-Powered Drug Discovery Stocks, one of which – Exscientia – was preparing to IPO. Here’s how those firms have performed since then (company names link to our research):

Company NameTickerMarket Cap ThenMarket Cap NowChange

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.